Objective:To relay the current knowledge on the interaction between cytokines, growth factors, and ovarian hyperstimulation syndrome (OHSS) and to propose a new insight into the pathogenesis of OHSS.
Methods:Major studies that have reported on the association between cytokines, growth factors, and OHSS were identified through MEDLINE searches and through the published literature.
Results:Several cytokines, as well as vascular endothelial growth factor, were found to have a role, either in the prediction or pathogenesis of OHSS. Moreover, intravenous immunoglobulin, which has an anticytokine nature and inhibits the secretion of various cytokines, was shown to prevent the development of OHSS.
Conclusions:Current knowledge indicates a close interaction between cytokines, growth factors, and OHSS. Further understanding of these interactions may lead to different understanding of ovarian hyperstimulation syndrome.
1. Golan A, Ron-El R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: An update review. Obstet Gynecol Surv1989;44:430-440.
2.
2. Polishuk W, Schenker J. Ovarian overstimulation syndrome. Fertil Steril1969;20:443-450.
3.
3. Morris RS, Wong IL, Do YS, et al. The pathophysiology of ovarian hyperstimulation syndrome: A proposal role of the ovarian derived prorenin to angiotensin cascade. Adv Exp Med Biol1995;377:391-398.
4.
4. Navot D, Margalioth EJ, Laufer N, et al. Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertil Steril1987;48:57-61.
5.
5. Pride S, Yuen B, Moon Y. Clinical, endocrinologic and intra-ovarian prostaglandin responses to H1 receptor blockade in the ovarian hyperstimulation syndrome: Studies in the rabbit model. Am J Obstet Gynecol1984;148:670-674.
6.
6. Zaidse I, Friedman M, Lindembaum E, Askenazi R, Perez B, Paldi E. Serotonin and the ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol1983;15:55-60.
7.
7. Leung P, Yuen B, Moon Y. Effect of prolactin in an experimental model of the ovarian hyperstimulation syndrome. Am J Obstet Gynecol1983;145:847-849.
8.
8. Schenker J, Polishuk W. The role of prostaglandins in the hyperstimulation syndrome. Obstet Gynecol1985;66:220-224.
9.
9. Ben-Rafael Z, Orvieto R. Cytokines-involvement in reproduction. Fertil Steril1992;58:1093-1099.
10.
10. McClure N, Healy DL, Rogers PAW, et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet1994;344:235-236.
11.
11. Goldsman MP, Pedram A, Dominguez CE, Ciuffardi I, Levin E, Asch RH. Increased capillary permeability induced by human follicular fluid: A hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertil Steril1995;63:268-272.
12.
12. Neulen J, Yan Z, Raczek S, et al. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permability factor in human granulosa cells: Importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab1995;80:1967-1971.
13.
13. Krasnow JS, Berga SL, Guzick DS, Zeleznik AJ, Yeo K-T. Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: A preliminary report. Fertil Steril1996;65:552-555.
14.
14. Abramov Y, Barak V, Nisman B, Schenker JG. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil Steril1997;67:261-265.
15.
15. Abramov Y, Schenker JG, Lewin A, Friedler S, Nisman B, Barak V. Plasma inflammatory cytokines correlate to the ovarian hyperstimulation syndrome. Hum Reprod1996;11:1381-1386.
16.
16. Friedlander MA, Loret de Mola JR, Goldfarb JM. Elevated levels of interleukin-6 in ascites and serum from women with ovarian hyperstimulation syndrome. Fertil Steril1993;60:826-833.
17.
17. Loret de Mola JR, Flores JP, Baumgardner GP, Goldfarb JM, Gindlesperger V, Friedlander MA. Elevated interleukin-6 levels in the ovarian hyperstimulation syndrome: Ovarian immunohistochemical localization of interleukin-6 signal. Obstet Gynecol1996;87:581-587.
18.
18. Loret de Mola JR, Baumgardner GP, Goldfarb JM, Firedlander MA. Ovarian hyperstimulation syndrome: Pre-ovulatory serum concentration of interleukin-6, interleukin-1 receptor antagonist and tumour necrosis factor-α cannot predict its occurrence. Hum Reprod1996;11:1377-1380.
19.
19. Revel A, Lavy Y, Antebi E, et al. Characterization of intraperitoneal factors involved in severe OHSS (abstract). Gynecol Endocrinol1995;9 (Suppl): FC70-FC70.
20.
20. Revel A, Barak V, Lavy Y, et al. Characterization of intraperitoneal cytokines and nitrites in women with severe ovarian hyperstimulation syndrome. Fertil Steril1996;66:66-71.
22. Orvieto R, Voliovitch I, Fishman P, Ben-Rafael Z. Interleukin-2 and ovarian hyperstimulation syndrome: A pilot study. Hum Reprod1995;10:24-27.
23.
23. Orvieto R, Genazzani AR, Petraglia F, Schwartz A, Shelef M, Ben-Rafael Z. Interleukin-2 production by cultured human granulosa cells. Int J Fertil Menopausal Stud1997;42:297-300.
24.
24. Abe Y, Horiuchi A, Miyake M, Kimura S. Anti-cytokine nature of natural human immunoglobulin: One possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev1994;139:5-19.
25.
25. Orvieto R, Achiron A, Margalit R, Ben-Rafael Z. The role of intravenous immunoglobulin in the prevention of severe ovarian hyperstimulation syndrome. J Assist Reprod Genet (In press).
26.
26. Wang LJ, Norman RJ. Concentrations of immunoreactive interleukin-1 and interleukin-2 in human preovulatory follicular fluid. Hum Reprod1992;7:147-150.
27.
27. Barak V, Mordel N, Zajicek G, Kalichman I, Treves AJ, Laufer N. The correlation between interleukin-2 and soluble interleukin-2 receptors to oestradiol, progesterone and testosterone levels in periovulatory follicles of in vitro fertilization patients. Hum Reprod1992;7:926-929.
28.
28. Levy T, Orvieto R, Homburg R, Dekel A, Peleg D, Ben-Rafael Z. Severe ovarian hyperstimulation syndrome despite low plasma estrogen levels in hypogonadotropic hypogonadal patient. Hum Reprod1996;11:1177-1179.
29.
29. Zalel Y, Orvieto R, Ben-Rafael Z, Homburg R, Fisher O, Insler V. Recurrent spontaneous ovarian hyperstimulation syndrome associated with polycystic ovary syndrome. Gynaecol Endocrinol1995;9:313-315.
30.
30. Friedman CI, Danforth DR, Herbosa-Encarnacion C, Arbogast L, Alak BM, Serifer DB. Follicular fluid vascular endothelial growth factor concentrations are elevated in women of advanced reproductive age undergoing ovulation induction. Fertil Steril1997;68:607-612.
31.
31. Yarali H, Fleige-Zahraka BG, Yuen BH, McComb PF. The ascites in the ovarian hyperstimulation syndrome does not originate from the ovary. Fertil Steril1993;59:657-661.
32.
32. Aboulghar MA, Mansour RT, Serour GI, Sattar MA, Amin YM, Elattar I. Management of severe ovarian hyperstimulation syndrome by ascitic fluid aspiration and intensive intravenous fluid therapy. Obstet Gynecol1993;81:108-111.
33.
33. Fakih H, Bello S. Ovarian cyst aspiration: A therapeutic approach to ovarian hperstimulation syndrome. Fertil Steril1992;58:828-832.
34.
34. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin-6 induces the expression of vascular endothelial growth factor. J Biol Chem1996;271:736-741.
35.
35.Ben-Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: A potential mechansim for inflammatory angiogenesis. FEBS Lett1995;372:83-87.
36.
36. Orvieto R, Ben-Rafael Z. The role of the immune system in severe ovarian hyperstimulation syndrome. Med Hypotheses1995;45:231-234.
